Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Scio-323 is an orally available p38 mitogen-activated protein (MAPK) kinase inhibitor.
説明 | Scio-323 is an orally available p38 mitogen-activated protein (MAPK) kinase inhibitor. |
ターゲット&IC50 | p38:< 0.005 µM, p38:1.5 µM |
In vivo | Oral treatment with the SCIO-323 included delivery for 3 weeks and stopping for 3 weeks, delivery for 3 weeks after an initial 3-week delay, and delivery for 6 weeks continuously. Administration of the SCIO-323 continuously for 6 weeks with/without the presence of particles, or for the initial 3 of 6 weeks had minor effects on bone ingrowth. After establishing a particle-induced chronic inflammatory reaction for 3 weeks, administration of SCIO-323 for a subsequent 3 weeks suppressed net bone formation. The activity of osteoclast-like cells remained low among all treatments when compared with the first control.[1] |
分子量 | 479.54 |
分子式 | C27H30FN3O4 |
CAS No. | 309913-51-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (57.35 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Scio-323 309913-51-7 MAPK p38 MAPK Inhibitor inhibitor inhibit